Neuroleptic malignant syndrome associated with the use of injection zuclopenthixol acetate.
Neuroleptic malignant syndrome
side effect
zuclopenthixol
Journal
Industrial psychiatry journal
ISSN: 0972-6748
Titre abrégé: Ind Psychiatry J
Pays: India
ID NLM: 101547239
Informations de publication
Date de publication:
Historique:
received:
25
06
2019
revised:
03
07
2020
accepted:
11
07
2020
entrez:
29
3
2021
pubmed:
1
1
2020
medline:
1
1
2020
Statut:
ppublish
Résumé
Zuclopenthixol is available in two parenteral formulation,i.e., in the form of acetate and decanoate. It has high affinity for dopamine D1 and D2 receptors. There is limited literature of association of neuroleptic malignant syndrome with the use of zuclopenthixol monotherapy. These case reports have mostly implicated zuclopenthixol decanoate, and also zuclopenthixol acetate. In this report, we present a case of neuroleptic malignant syndrome associated with use of zuclopenthixol acetate.
Identifiants
pubmed: 33776291
doi: 10.4103/ipj.ipj_54_19
pii: IPJ-29-162
pmc: PMC7989464
doi:
Types de publication
Case Reports
Langues
eng
Pagination
162-164Informations de copyright
Copyright: © 2020 Industrial Psychiatry Journal.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Neurohospitalist. 2011 Jan;1(1):41-7
pubmed: 23983836
Curr Neuropharmacol. 2015;13(3):395-406
pubmed: 26411967
Cureus. 2019 May 18;11(5):e4697
pubmed: 31338272
J Clin Psychopharmacol. 2000 Apr;20(2):281-3
pubmed: 10770479
S Afr Med J. 2011 May 25;101(6):405-7
pubmed: 21920075
Arukoru Kenkyuto Yakubutsu Ison. 1991 Oct;26(5):367-72
pubmed: 1772376
BMJ Case Rep. 2009;2009:
pubmed: 21686818
Br J Psychiatry. 1989 Apr;154:562-3
pubmed: 2590791
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD000525
pubmed: 22513898
World J Biol Psychiatry. 2009;10(4 Pt 2):644-7
pubmed: 17965986
Clin Toxicol (Phila). 2007;45(3):277-80
pubmed: 17453880